Next-generation pneumococcal conjugate vaccine development for LMICs
Inventprise is developing efficacious, affordable vaccines for global populations most in need. The foundation’s support is helping Inventprise advance the novel pneumococcal conjugate vaccine (IVT-25), which will be made available, accessible, and affordable to low- and middle-income countries. Inventprise will also make its platform available for future vaccine development.
- Focus areas
- Life Sciences
- Investment type
- Direct equity
- Status
- Active
- Initial investment
- Seed
- Partnered in
- 2021
- Headquarters
- USA
More about our work
Our focus
We embrace science and technology innovations that solve old problems in new ways, challenge status quos, and build on past breakthroughs. Our six domains of focus comprise 40+ program strategies across the foundation’s nearly $9B annual charitable support.
Investment Approach
How the Strategic Investment Fund is fostering partnerships with the private sector to leverage the globe’s most groundbreaking global innovations for societal good.
Our Team
The SIF Investment Committee brings depth of experience to global investment programs, with a proven track record of innovation across sectors and scale.